LRP Presents Lead Drug LRP-661 at EILAT XVII in Madrid, May 2024

London Research & Pharmaceuticals (LRP) recently showcased promising pre-clinical results for their leading compound, LRP-661, also known as Cannabidiol Sulphate (CBDS), at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) held in Madrid, Spain from May 5th to May 8th, 2024. The data presented by LRP underscores the compound’s superior safety, efficacy, bioavailability, and pharmacokinetics (PK) across multiple species.

LRP-661 stands out due to its improved oral formulation compared to traditional cannabidiol, marking a significant leap forward in epilepsy treatment. The compound demonstrated exceptional efficacy in various pre-clinical seizure models, including PTZ fully kindled mice, Maximal Electroshock Seizure (MES), MES Threshold, and pentylenetetrazol (PTZ)-induced seizures. Notably, LRP-661 exhibited an enhanced safety profile when compared to the current oral cannabidiol solution in sesame oil suspension. Key improvements include better gastrointestinal tolerability, absence of liver and renal toxicity, and a lower likelihood of drug-drug interactions.

The presentation of this data on May 7th, 2024, received high commendation from the conference organizer and Chair, Dr. Meir Bialer, highlighting the significance of LRP-661 in the ongoing development of epilepsy treatments. Recognizing the urgent need for innovative therapies in rare and challenging conditions, LRP is actively preparing orphan drug applications for both Dravet Syndrome and Lennox-Gastaut Syndrome. This designation is crucial as it streamlines the development and approval processes, providing essential incentives for further investment and innovation. This ultimately accelerates the availability of vital therapies for patients in need.

Moreover, LRP has announced plans to release compelling efficacy data in a Dravet syndrome model, reinforcing their commitment to addressing the unique challenges faced by patients with this disorder.

About LRP-661 (CBD Sulphate):

LRP-661 is the flagship compound of London Research & Pharmaceuticals. It is an orally available, semi-synthetic form of cannabidiol (CBD) with predictable dosing and formulation. The only currently available prescription formulation of cannabidiol is a sesame oil suspension known as Epidiolex®, which achieved sales of $845 million in 2023. LRP-661 has the potential to emerge as a significant player in the field of epilepsy treatment due to its promising properties.

About London Research & Pharmaceuticals:

London Research & Pharmaceuticals is committed to creating highly druggable formulations of existing compounds, focusing on addressing unmet medical needs. Besides LRP-661, the company has generated preclinical data on various other compounds targeting a range of diseases, including inflammation, infectious diseases, oncology, and psychiatric disorders. LRP remains open to partnership discussions for its proprietary compounds as it continues to drive innovation in drug discovery and development.